Isentress - 2007 FDA approvals

Drug: Isentress (raltegravir potassium)
Indication: HIV
Company: Merck
Approval Date: October 12, 2007

Scoop: Isentress is the first agent in the class of antiretroviral agents known as integrase inhibitors. The drug is designed to slow the advancement of HIV-1 infection by blocking the HIV integrase enzyme that the virus needs in order to multiply. The drug is forecasted to reach $900 million in sales by 2012.

More news:
FDA approves Isentress. Report
FDA panel endorses Merck's new AIDS drug. Report

Isentress - 2007 FDA approvals

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.